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Background/aim: Changes in collagen metabolism and fibroblastic activity may play a role in the pathogenesis of brucellosis. The
prolidase enzyme plays an important role in collagen synthesis. We aimed to investigate the association of prolidase levels with brucellosis.
Materials and methods: Serum prolidase levels in 20 patients newly diagnosed with brucellosis were compared with levels in 30 healthy
control subjects. Patients with brucellosis were reassessed 3 months later for prolidase, other laboratory measurements, and response
to treatment.
Results: The levels of serum prolidase were significantly higher in brucellosis patients compared with those of healthy controls. Prolidase,
sedimentation, and C-reactive protein levels were significantly lower after antibrucellosis treatment than before treatment.
Conclusion: The current study is the first to demonstrate significantly increased serum prolidase levels in patients with brucellosis
compared with healthy controls. Prolidase levels also significantly decreased with antibrucellosis treatment. This finding provides a new
experimental basis to understand the pathogenesis of brucellosis in relation to collagen metabolism. The increase in serum prolidase
levels might be related to several factors such as tissue destruction, increased fibroblastic activity, and granuloma formation, all of which
are involved in the natural history of brucellosis.
Key words: Prolidase, brucellosis, pathogenesis, collagen, treatment

1. Introduction
The clinical presentation of brucellosis is nonspecific and
the course of infection is variable. Brucellosis presents as
a multisystem disease involving many organs and tissues
[1]. The mechanisms underlying the manifestations of
brucellosis are not completely understood. Furthermore,
biopsied samples of tissues in patients with brucellosis
may show noncaseating granulomas, but the molecular
mechanism underlying this change remains unclear.
Prolidase is a cytosolic exopeptidase that
splits imidodipeptides with C-terminal proline or
hydroxyproline. This enzyme has a major role in recycling
proline from imidodipeptides for collagen resynthesis
and cell growth. Therefore, prolidase is considered to be
a limiting factor in the regulation of collagen production
[2]. Prolidase activity has been reported in leukocytes,
erythrocytes, plasma, and various organs such as the brain,
heart, kidney, uterus, thymus, and dermal fibroblasts [3].

Serum prolidase enzyme activity is elevated in conditions
that are characterized by chronic inflammation of tissue
and/or increased turnover of collagen. We hypothesized
that serum prolidase levels may be associated with
brucella infection, brucellosis-related tissue damage, and
granuloma formation.
In this study, we explored prolidase levels in patients
with brucellosis and healthy controls. We revealed the
relationship between the prolidase level and changes in
clinical status and disease activity in order to clarify the
role of prolidase in the pathogenesis of brucellosis. To our
knowledge, there is no published data regarding prolidase
levels in patients with brucellosis.
2. Materials and methods
2.1. Study design and participants
This prospective study included 20 patients who were
newly diagnosed with brucellosis recruited from the
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internal medicine and infectious disease clinic of our
hospital from January 2017 to December 2017. Thirty
sex-matched healthy controls (HC) who visited our
hospital in the same period were enrolled in this study.
HCs did not have any history of brucellosis. Patients with
brucellosis were reassessed 3 months later for prolidase
measurement and response to treatment. We did not
have data loss during the follow-up of the patients with
brucellosis. Written informed consent was provided by
each participant, and the study protocol was approved by
the Local Ethics Committee.
The exclusion criteria for patients with brucellosis
were as follows: history of malignant cancers, concomitant
presence of any inflammatory disease, any rheumatic
diseases, any endocrine disease (diabetes mellitus,
parathyroid or thyroid disease), or chronic renal or hepatic
disease, as well as patients who were currently receiving
antibrucellosis therapy.
Healthy controls were volunteers who had no evidence
of acute or chronic infectious disorders, autoimmune
disease, or any other systemic condition.
Clinical data from each patient including age, sex,
occupation, residence, transmission route, symptoms at
diagnosis, physical examination findings, weight, height,
and current medications were recorded. Laboratory
assessment included complete blood count, C-reactive
protein (CRP), sedimentation (ESR), and liver and
kidney function tests. Blood specimens were taken
from each patient following an overnight fast before the
antibrucellosis therapy and 3 months after treatment.
Serum was stored at −80 °C until analysis for prolidase
level.
2.2. Diagnosis of brucella
Cases who had musculoskeletal pain, fever of unknown
origin, and acute or chronic arthritis were suspected to
have brucellosis according to their clinical manifestations.
The diagnosis of brucellosis was established for patients
presenting with symptoms suggestive of brucellosis
according to the presence of one of the following criteria;
1. Wright titer of equal or greater than 1/160 and
2-mercaptoethanol (2ME) test of ≥1/80.
2. Brucellosis-positive blood, bone marrow, and
synovial fluids culture.
Relevant demographic, clinical, and laboratory data
and treatment modalities and outcomes were obtained
from patients’ follow-up cards and hospital records.
2.3. Measurement of serum prolidase level
Serum prolidase level was measured by doubleantibody sandwich technique using an enzyme-linked
immunosorbent assay (ELISA) kit (Shanghai Sunred
Biological Technology Co. Ltd., Shanghai, China). Assay
range was 0.5–150 ng/mL, and intraassay CV was <10%.
The concentrations of the samples were calculated through
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calibration curves obtained from study standards with
known levels. Serum prolidase level was expressed as ng/
mL.
2.4. Statistical analysis
Data are expressed as mean ± standard deviation (SD) or
number (percentages). The normality and the homogeneity
of the data were examined by the Shapiro–Wilk test and
Levene test, respectively. Comparisons between groups
for continuous variables were performed using Student’s
t-test (normal distribution) or the Mann–Whitney U test
(nonnormal distribution). The Fisher test or the χ2 test
was used for all categorical data. A paired sample t-test was
conducted to compare the two measurements of patients
for prolidase levels at baseline and 3 months later. For all
calculations, SPSS statistical package (version 15.0; SPSS,
Chicago, IL, USA) was used. P < 0.05 was considered
statistically significant.
3. Results
We included 20 patients newly diagnosed with brucellosis
and 30 healthy controls in this study. In the case group, 8
were male (40%) and 12 were female (60%), with a mean
age of 48.5 ± 15.4 years. Doxycycline and streptomycin
were the most frequently used therapeutic regimens
(95%) in the patients. One patient received trimethoprim
sulfamethoxazole and doxycycline because of ototoxicity
and liver function test abnormalities due to previous
treatment. All patients received treatment for at least 6
weeks. Only one patient received treatment for 12 weeks.
Relapse occurred in only one patient after treatment.
Hematological findings were pancytopenia (10%) and
thrombocytopenia (5%). Osteoarticulary findings of the
patients were as follows: 1 patient had spondylodiscitis, 2
patients had sacroiliitis, and 1 patient had arthritis.
The demographic data of the patients with brucellosis
and the control group are shown in Table 1. There were
no significant differences in sex between groups; however,
the ages of patients were significantly higher than those of
the controls (P = 0.001). There were significant differences
between patients with brucellosis and healthy controls
with respect to prolidase level. The serum prolidase level
was significantly higher in patients with brucellosis than in
the control group (P < 0.001). The patients were classified
as having acute, subacute, or chronic brucellosis according
to the duration of their disease: <8 weeks, 8–52 weeks, and
>52 weeks, respectively. There were 9 patients with acute, 6
with subacute, and 5 with chronic brucellosis. There was no
statistically significant difference in serum prolidase levels
among acute, subacute, and chronic cases with brucellosis
(85.9 ng/mL, 110.2 ng/mL, and 114.8 ng/mL, respectively;
P = 0.332). The clinical characteristics of the patients with
brucellosis are summarized in Table 2.
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Table 1. The demographic data and prolidase level of the patients with brucellosis and
control group.
Variable

Control group
(n = 30)

Patients with brucellosis
(n = 20)

P-value

Age

34.1 ± 8.1

48.5 ± 15.4

0.001

Sex, F/M

12 (40)/18 (60)

8 (40)/12 (60)

1.000

Prolidase level, ng/mL

40.8 ± 8.9

100.4 ± 38.9

<0.001

F: female, M: male.

Table 3 summarizes the serum prolidase levels, ESR,
CRP, and other laboratory parameters of patients with
brucellosis before and 3 months after antibrucellosis
treatment. Prolidase levels, ESR, and CRP were significantly
lower after antibrucellosis treatment than before treatment.
Only 1 patient relapsed after treatment, and the prolidase
level of that patient was higher than the pretreatment level
(135.6 ng/mL and 151.5 ng/mL, respectively).
4. Discussion
The prolidase enzyme, which has a role in the final step
of collagen breakdown, is present in various tissues and
plasma [3]. This enzyme plays an important role in the
recycling of proline for collagen synthesis and cell growth
[4]. During protein catabolism, prolidase catalyzes the
degradation of intracellular collagen; its activity may be
correlated with the rate of collagen degradation [5]. Due to
the fact that brucella is a disease that affects many systems,
it is very likely that it affects the metabolism of collagen
in many tissues of the body [6]. Based on these data, the
presence of a significant association between prolidase
level and brucellosis can be considered.
Changes in prolidase activity may play important
roles in extracellular matrix turnover, and therefore
may also play a role in the development and outcome of
several diseases [7,8]. Prolidase enzyme activity has been
investigated in various disorders [9–12]. An increase
or decrease in prolidase activity can demonstrate the
existence of a disease state as well as the progression of the
condition. Although some authors suggest that prolidase
activity decreases in some disease conditions, such as
asthma [13], chronic obstructive pulmonary disease
[14], and ankylosing spondylitis [15], increased prolidase
activity has been reported in some other diseases and
cancers (pancreatic cancer, lung carcinoma, breast cancer)
[16–19]. In subjects with chronic liver disease (chronic
hepatitis B and C) and nonalcoholic steatohepatitis, serum
prolidase activity has been shown to increase, especially
in the early stage of fibrosis [20–23]. To the best of our
knowledge, there is no existing data concerning the serum
prolidase levels in patients with brucellosis.

Table 2. Clinical characteristics of patients with brucellosis.
Variables

Patients with brucellosis
(n = 20)

Occupation, n (%)
livestock ranger

10 (50)

house wife

4 (20)

veterinarian

1 (5)

other

5 (25)

Residence
rural area

10 (50)

city

10 (50)

Transmission route
nonpasteurized milk products

11 (55)

animal contact

4 (20)

nonpasteurized milk products and
animal contact

5 (25)

Symptoms at diagnosis
fatigue

20 (100)

sweating

20 (100)

arthralgia

18 (90)

fever

13 (65)

lumbago

11 (55)

weight loss

3 (15)

lack of appetite

17 (85)

nausea

3 (15)

headache

5 (25)

Hepatomegaly

4 (20)

Splenomegaly

2 (10)

Osteoarticular findings

5 (25)
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Table 3. Serum prolidase levels and other laboratory parameters of patients with brucellosis
before and after 3 months of antibrucellosis treatment.
Variables

Before treatment

After treatment

P-value

Prolidase, ng/mL

100.4 ± 38.9

88.1 ± 46.4

0.049

22.6 ± 43.5

3.7 ± 1.5

0.001

White blood cell count, 10 /µL

8.93 ± 4.42

7.18 ± 1.67

0.204

Hemoglobin, g/dL

14.6 ± 1.6

14.9 ± 1.7

0.398

Sedimentation, mm/hour

12.7 ± 11.3

7.4 ± 7.1

0.002

AST, U/I

52.1 ± 75.9

37.8 ± 59.1

0.351

50.8 ± 56.1

45.2 ± 85.6

0.058

Platelets, 10 /µL

252 ± 91

247 ± 70

0.823

Blood urea nitrogen, mg/dL

15.1 ± 4.3

14.9 ± 8.3

0.176

C-reactive protein, mg/L
3

ALT, U/I
3

AST: aspartate aminotransferase, ALT: alanine aminotransferase.

The current study is the first to demonstrate significantly
increased serum prolidase levels in patients with
brucellosis compared with healthy controls. This finding
suggests that brucellosis causes collagen tissue damage and
increased collagen turnover; therefore, prolidase enzyme
activity is increased in brucellosis. The present study is
also the first to evaluate both prolidase levels and disease
activity. We found that the prolidase levels significantly
decreased with antibrucellosis treatment. These results
demonstrated that the pathogenesis of brucellosis could
be elucidated by the collagen metabolism. Synovial
fibroblast may play an important role in the pathogenesis
of osteoarticular diseases in brucellosis [24]. Fibroblastic
activity during the natural history of brucellosis might be
another contributing factor for increased serum prolidase
level.
Brucellosis has both acute and chronic properties of
inflammation. Therefore, increased CRP and ESR have
been reported to be involved in active disease and are often
considered as useful criteria for the diagnosis and followup on the effectiveness of treatment in brucellosis [1,25].
In our study, the highest levels of prolidase, ESR, and CRP
were seen in the patients with acute brucellosis. However,
prolidase, ESR, and CRP levels decreased significantly
with treatment. This result suggests that prolidase may
be an important parameter in evaluating the response
to treatment and may be used as a possible indirect
inflammatory marker in patients with brucellosis.
Host protease disorders can cause granuloma formation,
leading to collagen degradation and tissue damage. Myara
et al. demonstrated higher plasma prolidase activity in the
early stage of chronic liver disease, indicating its role in
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extracellular matrix formation [9]. In different studies,
higher serum prolidase activities were found in patients
with pulmonary tuberculosis, especially in patients with
lung cavities [26,27]. It has been suggested that increased
prolidase levels might be related to tissue damage and
enhanced fibroblast activity. In patients with brucellosis,
biopsy of the affected organ may reveal noncaseating
granulomas. Therefore, we can speculate that increased
serum prolidase levels might be related to tissue damage,
enhanced fibroblastic activity, and granuloma formation.
Future studies which include tissue biopsy may give better
understanding of this situation.
Our study has several limitations. First, it had a
relatively small sample size. Second, we did not perform
tissue biopsy. It would be very useful to be able to detect
the formation of granuloma and other pathological
findings. However, this is a preliminary study providing
information regarding collagen metabolism in patients
with brucellosis by evaluating serum prolidase levels.
We revealed increased prolidase levels in patients with
brucellosis. This finding provides a new experimental
basis for understanding the pathogenesis of brucellosis.
The increase in serum prolidase levels might be related
to several factors such as tissue destruction, increased
fibroblastic activity, and granuloma formation, all of
which are involved in the natural history of brucellosis.
This may be interpreted as evidence of increased collagen
turnover in brucellosis. Monitoring serum prolidase level
in clinical practice may be a suitable and useful method for
evaluating patients with brucellosis. Further prospective
studies are required to cross-validate our findings in larger
cohorts of patients with brucellosis.
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